Description
The domain expert noted poor CNS penetration of existing autophagy enhancers like rapamycin, but alternative delivery methods weren’t explored. This pharmacokinetic barrier represents a major obstacle to translating proteostasis-based therapies.
Source: Debate session sess_SDA-2026-04-01-gap-012 (Analysis: SDA-2026-04-01-gap-012)